KAEDI and PORTON deepened their strategic cooperation to jointly promote the global development of cell therapy drugs
On June 30, 2023, Suzhou PORTON Biopharmaceutical Co., Ltd. (hereinafter referred to as PORTON) and Nanjing KAEDI Technology Co., Ltd. (hereinafter referred to as KAEDI) held a strategic cooperation signing ceremony to deepen the cooperation in the R&D and production of cell therapy drugs, and jointly promote the development of new drugs in China, the United States and even the global market.
In March this year, the clinical trial application (IND) of KD-025 cell injection of the CAR-T project for solid tumors independently developed by KAEDI was tacitly approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. As the exclusive CDMO partner, PORTON Biotech provided CMC research and development services for the project, including process development and production of plasmids, viruses, CAR-T cells, and IND registration support for the CMC part.
PORTON has an end-to-end gene and cell therapy CDMO service platform, covering plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy and live bacterial therapy. The signing of this agreement will further strengthen the strategic cooperation between the two parties, expand the IND filing in the United States, clinical and commercial production of cell therapy drugs, and accelerate the global research and development process of the drug on the basis of the existing cooperation.
In March this year, the clinical trial application (IND) of KD-025 cell injection of the CAR-T project for solid tumors independently developed by KAEDI was tacitly approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. As the exclusive CDMO partner, PORTON Biotech provided CMC research and development services for the project, including process development and production of plasmids, viruses, CAR-T cells, and IND registration support for the CMC part.
PORTON has an end-to-end gene and cell therapy CDMO service platform, covering plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy and live bacterial therapy. The signing of this agreement will further strengthen the strategic cooperation between the two parties, expand the IND filing in the United States, clinical and commercial production of cell therapy drugs, and accelerate the global research and development process of the drug on the basis of the existing cooperation.
Yu Yan, Deputy General Manager of Marketing Department of PORTON Biologics, said: "We are very grateful to KAEDI for its trust and support to PORTON Biologics, and we are honored that we can support the IND application of CAR-T project in China, PORTON Biologics has a professional team and rich project experience, which can support the international application of gene and cell therapy drugs, and believe that it can help KEDI Medical's breakthrough in the global research and development of new drugs, so that good drugs can benefit the public earlier."Dr. Dai Hongjiu, Founder, CEO and Chairman of KAEDI, said, "We are very pleased to strengthen our strategic partnership with PORTON Biologics, With the development of several new cell therapy drug development pipelines and the approval of the first cell therapy product targeting NKG2DL in China this year, we believe that with the professional team and platform of PORTON Biologics, which can help KAEDI achieve IND application and commercialization of cell therapy drugs in the United States and even around the world."
About PORTON
Founded in December 2018, based in Suzhou Industrial Park, Suzhou PORTON Biopharmaceutical Co., Ltd. has built a CDMO platform integrating plasmids, viral vectors and cell therapy products based on the listed company - Chongqing PORTON Pharmaceutical Technology Co., Ltd. (stock code: 300363), providing clinical and new drug clinical trial applications (IND), registered clinical trial samples and commercial production services from early research, investigator-initiated clinical trial applications (INDs), registered clinical trial samples and commercial production services, accelerating the process of drug research and transformation.
On the basis of the successful experience of PORTON Co., Ltd., with world-class professionals as the core, adhering to the service tenet of "customer first", and taking "compliance, professionalism, focus, openness and collaboration" as the brand concept, PORTON Biotech continues the parent company's strong IP protection and project management mechanism and perfect quality management system, makes full use of the core team's successful experience in promoting gene and cell therapy products to clinical trials and marketing, provides high-quality and efficient services to global customers, and makes good drugs benefit the public earlier.
About KAEDI Medical
KAEDI is a clinical-stage drug discovery and development company dedicated to developing novel cell drugs with unmet clinical needs in patients with solid tumors using a leading synthetic biology technology platform. Relying on KD-SmCAR™ and KD-ScCAR™, the company's independent CAR library screening platform, and KD-ScCAR™, a dual-targeted CAR development platform. KAEDI has successfully developed a number of new cell drug pipelines for solid tumors, including next-generation autologous and allogeneic CAR-T/CAR-NK pipelines. At present, more than 30 CAR-related patents have been declared and 15 patents have been authorized, among which the core pipeline KD-025, KD-496 and other patents are authorized for the first time in China and the United States. The product development results of KD-025 CAR-T targeting NKG2DL for liver cancer, colorectal cancer and glioma have been published in the international authoritative journal "Journal for ImmunoTherapy of Cancer", "Cancer Immunology Research" and the American annual cancer clinical meeting ASCO. The KD-025 CAR-T IIT clinical trial carried out in a well-known clinical center in China has completed a number of low-dose administrations without obvious toxic side reactions, and the product is safe and effective, and it is the first domestic KEDI is headquartered in Nanjing, China. For more information, please visit the official website of Nanjing KAEDI Technology Co., Ltd.:targeting CAR-T (KD-025) cells targeting NKG2DL solid tumors. The company that IND applied for CDE clinical approval is currently negotiating with a number of partners to start the first clinical phase of KD-025 registration, and at the same time, the company's core product KD-496 has entered the IIT clinical stage as the world's first new dual-targeted CAR-T cell injection. In addition, KAEDI is promoting the layout of the next generation allogeneic universal CAR-T/CAR-NK, and is expected to build KAEDI into a world-renowned solid tumor cell therapy company in the near future. The company has built a 3,000 square meters GMP cell drug R&D and production center, completed nearly 100 million yuan of financing, and is carrying out B round financing, At the same time, the company is rapidly advancing the development and commercialization of synthetic biology products through strategic cooperation.